NHS-Novartis deal could change how pharmas work with integrated systems

A Sept. 1 agreement between NHS and Novartis could establish a template for how medications are distributed in integrated health systems, with cardiovascular, diabetic and respiratory disease therapies the most likely candidates for adopting the model next. 

The key feature of the arrangement is that Novartis AG (NYSE:NVS; SIX:NOVN) and the U.K.’s healthcare system will work together to proactively identify patients with persistently high cholesterol and invite them to get treated with the company’s new cholesterol-lowering drug Leqvio inclisiran. ...